Claims for Patent: 9,200,324

Summary for Patent: 9,200,324

Title:	Biomarkers and methods for measuring and monitoring inflammatory disease activity
Abstract:	Biomarkers useful for diagnosing and assessing inflammatory disease are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. The biomarkers include at least two biomarkers selected from the DAIMRK group and the score is a disease activity index (DAI).
Inventor(s):	Cavet; Guy L. (Burlingame, CA), Shen; Yijing (San Mateo, CA), Knowlton; Nicholas (Choctaw, OK), Centola; Michael (Oklahoma City, OK)
Assignee:	CRESCENDO BIOSCIENCE (South San Francisco, CA) OKLAHOMA MEDICAL RESEARCH FOUNDATION (Oklahoma City, OK)
Application Number:	12/905,984
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,200,324
Patent Claims:	1. A method for generating quantitative data for a first subject comprising: performing at least one immunoassay on a first sample from the first subject to generate a first dataset comprising the quantitative data, wherein the quantitative data represents at least twelve protein markers comprising: chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1); C-reactive protein, pentraxin-related (CRP); epidermal growth factor (beta-urogastrone) (EGF); interleukin 6 (interferon, beta 2) (IL6); leptin (LEP); matrix metallopeptidase 1 (interstitial collagenase) (MMP1); matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3); resistin (RETN); serum amyloid A1 (SAA1); tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A); vascular cell adhesion molecule 1 (VCAM1); and, vascular endothelial growth factor A (VEGFA); and wherein the first subject has rheumatoid arthritis (RA) or is suspected of having RA. 2. The method of claim 1, wherein the at least twelve protein markers consist of: IL6, EGF, VEGFA, LEP, SAA1, VCAM1, CRP, MMP1, MMP3, TNFRSF1A, RETN, and CHI3L1. 3. The method of claim 1, wherein performance of the at least one immunoassay comprises: obtaining the first sample, wherein the first sample comprises the protein markers; contacting the first sample with a plurality of distinct reagents; generating a plurality of distinct complexes between the reagents and markers; and detecting the complexes to generate the data. 4. The method of claim 1, wherein the at least one immunoassay comprises a multiplex assay.

Details for Patent 9,200,324

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2029-10-15